What question did this study set out to answer?

This trial aimed to evaluate the effectiveness and safety of pembrolizumab and necitumumab in advanced non-small-cell lung cancer patients with significant PD-L1 expression.

July 29, 2026Clinical Cancer Research

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial

View Full Paper

Ask AI

Bookmark

This trial aimed to evaluate the effectiveness and safety of pembrolizumab and necitumumab in advanced non-small-cell lung cancer patients with significant PD-L1 expression.
Conducted as a nonrandomized, multicenter, open-label, single-arm phase II trial.
Included 50 patients with untreated advanced NSCLC and PD-L1 expression ≥50%.
Administered pembrolizumab and necitumumab every 3 weeks for up to 35 cycles.
Achieved an objective response rate (ORR) of 76.0% (95% CI: 61.9–86.9; P<0.0001).
Median progression-free survival (PFS) was 15.7 months; median overall survival (OS) not reached.
Most common treatment-related adverse events were rash (64.0%) and hypomagnesemia (60.0%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Nonrandomized trial investigates efficacy and safety of pembrolizumab and necitumumab in advanced NSCLC, indicating promising outcomes.

Cite This Study

Horiike et al. (2026) studied this question.

synapsesocial.com/papers/6a69a2d4c8da07d9defa6bd3 https://doi.org/10.1158/1078-0432.ccr-25-2751

View Full Paper

Ask AI

Bookmark

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial

Key Points

Discussion

Implication

Cite This Study

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider